Program
Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes
Also written as “Descartes-08” and “Descartes 08”.
Its studies are mostly in Multiple Myeloma · Myositis · Myasthenia Gravis · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · Lupus Erythematosus, Systemic, led by Cartesian Therapeutics.
Drug pageAutologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Cartesian Therapeutics | 64 open or running | phase 2since Oct 29, 2019 | Jan 24, 2018 | Dec 1, 2026phase 2 · NCT06038474 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 24, 2018First study: phase 1 study in Multiple MyelomaFirst studyNCT03448978 · 32 enrolled · United States
- Oct 29, 2019Phase 2 study in Myasthenia GravisNCT04146051 · 30 enrolled · United States, Canada
- Mar 23, 2021Phase 2 study in Multiple MyelomaNCT04816526 · 13 enrolled · United States
- Sep 8, 2023Phase 2 study in Lupus Erythematosus, SystemicNCT06038474 · 6 enrolled · United States
- Jul 20, 2025Phase 2 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT07089121 · 50 planned · United States
- Jan 29, 2026Phase 2 study in Antisynthetase syndromeNCT07391605 · 60 planned · United States
Ahead
- Dec 1, 2026Primary completion: phase 2 study in Lupus Erythematosus, SystemicNCT06038474
- Nov 2027Primary completion: phase 2 study in Antisynthetase syndromeNCT07391605
- Dec 2027Primary completion: phase 2 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT07089121
TargetBeta
“A preparation of autologous CD8-positive T-lymphocytes that have been genetically modified via transient mRNA transfection to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily me”NCIt, by rule
Other programs on TNFRSF17
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| elranatamabrule | Pfizer | phase 4 | 15 |
| linvoseltamabrule | Regeneron Pharmaceuticals | phase 4 | 13 |
| teclistamabrule | Johnson & Johnson | phase 4 | 11 |
| belantamab mafodotinrule | GlaxoSmithKline | phase 3 | 25 |
| Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F | AstraZeneca | phase 3 | 12 |
| etentamig | AbbVie | phase 3 | 11 |
| ramantamig | Johnson & Johnson | phase 3 | 8 |
| anitocabtagene autoleucelrule | Gilead Sciences | phase 3 | 6 |
| equecabtagene autoleucelrule | nanjing-iaso-biotechnology-co-ltd | phase 3 | 5 |
| Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934 | Sino Biopharmaceutical | phase 3 | 4 |
| GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003rule | Innovent Biologics | phase 3 | 4 |
| Evarucabgene Autoleucelrule | nexcella-inc | phase 3 | 2 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07391605Antisynthetase syndrome · United States | 2 | Recruiting | Nov 2027 | 60 |
| NCT07089121Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · United States | 2 | Recruiting | Dec 2027 | 50 |
| NCT06038474Lupus Erythematosus, Systemic · United States | 2 | Active, not recruiting | Dec 1, 2026 | 6 |
| NCT04816526Multiple Myeloma · United States | 2 | Terminated | Aug 4, 2022 | 13 |
| NCT04146051Myasthenia Gravis · United States, Canada | 2 | Active, not recruiting | Jan 5, 2026 | 30 |
| NCT03448978Multiple Myeloma · United States | 1 | Terminated | Apr 19, 2021 | 32 |
How it is read
Names in the registry
- “Descartes-08”, 5 entries
- “Descartes 08”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 2 studies
- Myositis, 1 study
- Myasthenia Gravis, 1 study
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, 1 study
- Lupus Erythematosus, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.